MedTrace Logo

A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females

NCT00547469 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2008-04-08

No results posted yet for this study

Summary

This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

DDP733

Sponsors & Collaborators

  • Dynogen Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Dynogen Study Director, MD · Dynogen Pharmaceuticals, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00547469 on ClinicalTrials.gov